- Plus Therapeutics Inc (NASDAQ:PSTV) has entered into an agreement with RadioMedix Inc to produce the company’s radiopharmaceuticals commercially.
- “This strategic partnership substantially supports our efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM),” said Marc Hedrick, President & CEO of Plus Therapeutics.
- 186RNL is being developed to treat recurrent GBM, leptomeningeal metastases, and pediatric brain cancer.
- Related Content: Recently, Plus Therapeutics presented data from a Phase 1 ReSPECT trial evaluating Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma (GBM).
- Price Action: PSTV shares are up 14.2% at $2.17 during the market session on the last check Thursday.
Geely Premium EV Brand Zeekr Is Exploring IPO Options, Including U.S., Hong Kong Listing
-Bloomberg
https://www.bloomberg.com/news/articles/2022-08-25/geely-premium-ev-brand-zeekr-is-said-to-explore-ipo-options?sref=2h1zKciy#xj4y7vzkg
